Miracle Mile Advisors LLC Has $555,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Miracle Mile Advisors LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,579 shares of the biopharmaceutical company’s stock after buying an additional 255 shares during the period. Miracle Mile Advisors LLC’s holdings in Gilead Sciences were worth $555,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of GILD. Tompkins Financial Corp boosted its stake in Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 241 shares in the last quarter. Fortitude Family Office LLC acquired a new stake in Gilead Sciences during the fourth quarter worth $29,000. Private Wealth Management Group LLC acquired a new stake in Gilead Sciences during the fourth quarter worth $29,000. Sachetta LLC acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $30,000. Finally, Rakuten Securities Inc. acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $33,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD opened at $68.64 on Tuesday. The stock has a market capitalization of $85.52 billion, a P/E ratio of 190.67, a P/E/G ratio of 2.92 and a beta of 0.18. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $87.86. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. The business has a 50-day moving average price of $65.98 and a two-hundred day moving average price of $72.51.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping the consensus estimate of ($1.49) by $0.17. The firm had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the business posted $1.37 EPS. Equities analysts predict that Gilead Sciences, Inc. will post 3.75 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Stockholders of record on Friday, June 14th were paid a $0.77 dividend. The ex-dividend date of this dividend was Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.49%. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Wall Street Analyst Weigh In

GILD has been the topic of several recent analyst reports. Robert W. Baird restated a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a research note on Thursday, June 20th. Morgan Stanley reduced their target price on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. Oppenheimer restated an “outperform” rating and issued a $105.00 target price on shares of Gilead Sciences in a research note on Friday, April 19th. TD Cowen reduced their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Friday, April 26th. Finally, Barclays reduced their target price on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating on the stock in a research note on Monday, April 29th. Twelve investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Gilead Sciences presently has a consensus rating of “Hold” and a consensus price target of $83.47.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now directly owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.29% of the stock is currently owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.